Literature DB >> 11143833

Impact of risperidone on seclusion and restraint at a state psychiatric hospital.

K N Chengappa1, J Levine, R Ulrich, H Parepally, J S Brar, R Atzert, R Brienzo, A Gopalani.   

Abstract

OBJECTIVE: To evaluate the impact of risperidone on seclusion and restraint in patients at a state psychiatric facility, shortly after risperidone's release.
METHODS: Patients who were in the hospital for at least 3 months prior to receiving risperidone and subsequently received risperidone for at least 3 months formed the cohort. A mirror-image design was used with duration to a maximum of 1 year before and 1 year after initiation of risperidone. The hospital population that did not receive either risperidone or clozapine during the same time period was used for comparison of trends of seclusion and restraint.
RESULTS: Seventy-four patients (most with schizophrenia) met the inclusion criteria of the risperidone group. There were statistically significant decreases in the number of seclusion hours (2.2 [SD 5.5] to 0.26 [SD 0.06]) and of events (0.23 [SD 0.59] to 0.05 [SD 0.14]) per person per month during risperidone treatment, compared with the prerisperidone treatment period (P = 0.01). The comparison group also evidenced decreases on these measures during the same time period, but the risperidone-treated cohort achieved a proportionally greater reduction. There were similar trends toward reduction in the restraint measures during risperidone treatment compared with prerisperidone, but these did not achieve statistical significance. The comparison group also showed slightly decreased use of restraints over the study period.
CONCLUSIONS: Risperidone appears to have had a positive impact on seclusion in this state-hospital psychiatric population. These data support the positive impact of risperidone on violence found in other studies. Violence and aggression are major factors that affect morale among psychiatric patients and staff. So, any benefit in this regard as a result of antipsychotic drug treatment is salutary for patients, families, and health care providers.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11143833     DOI: 10.1177/070674370004500907

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  4 in total

1.  Recommendations for pharmacological management of inpatient aggression in children and adolescents.

Authors:  Parikshit Deshmukh; Guarav Kulkarni; Drew Barzman
Journal:  Psychiatry (Edgmont)       Date:  2010-02

Review 2.  Pharmacological treatment of psychotic agitation.

Authors:  Glenn W Currier; Adam Trenton
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

3.  Reducing restraint use in a public psychiatric inpatient service.

Authors:  Robert E McCue; Leonel Urcuyo; Yehezkel Lilu; Teresa Tobias; Michael J Chambers
Journal:  J Behav Health Serv Res       Date:  2004 Apr-Jun       Impact factor: 1.505

Review 4.  Pharmacotherapy of Primary Impulsive Aggression in Violent Criminal Offenders.

Authors:  Alan R Felthous; Bridget McCoy; Jose Bou Nassif; Rajat Duggirala; Ellen Kim; Fulvio Carabellese; Matthew S Stanford
Journal:  Front Psychol       Date:  2021-12-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.